These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3850711)

  • 1. Reduced cofactor function of human high molecular weight kininogen induced by rat plasma kallikrein.
    Hoem NO; Briseid K
    Acta Pharmacol Toxicol (Copenh); 1985 Jul; 57(1):47-52. PubMed ID: 3850711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced cofactor function of human high molecular weight kininogen induced by human plasma kallikrein.
    Johansen HT; Briseid K
    Acta Pharmacol Toxicol (Copenh); 1984 Jul; 55(1):25-32. PubMed ID: 6431752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced or unchanged cofactor function of human high molecular weight kininogen induced by human plasma kallikrein.
    Johansen HT; Briseid K
    Adv Exp Med Biol; 1986; 198 Pt A():147-53. PubMed ID: 3492869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of factor XII in human plasma: protection by benzamidine of the cofactor function of high molecular weight kininogen.
    Briseid K; Johansen HT
    Acta Pharmacol Toxicol (Copenh); 1983 Oct; 53(4):344-52. PubMed ID: 6685967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dextran-induced lowering of plasminogen proactivator and functionally active high molecular weight kininogen in the rat.
    Berstad J; Briseid K
    Acta Pharmacol Toxicol (Copenh); 1982 May; 50(5):342-9. PubMed ID: 6180597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separation of plasma kallikrein and a kallikrein-like plasminogen activator generated by acetone in rat plasma.
    Johansen HT; Briseid K
    Acta Pharmacol Toxicol (Copenh); 1983 May; 52(5):371-80. PubMed ID: 6554030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of factor XII in acetone-treated human plasma: significance of the functional state of plasma kallikrein for the extent of activation.
    Hoem NO; Briseid K
    Acta Pharmacol Toxicol (Copenh); 1986 Aug; 59(2):144-50. PubMed ID: 3490738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin.
    Kleniewski J; Blankenship DT; Cardin AD; Donaldson V
    J Lab Clin Med; 1992 Jul; 120(1):129-39. PubMed ID: 1535355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rat plasma high-molecular-weight kininogen. A simple method for purification and its characterization.
    Hayashi I; Kato H; Iwanaga S; Oh-ishi S
    J Biol Chem; 1985 May; 260(10):6115-23. PubMed ID: 3846594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and characterization of two kinds of low molecular weight kininogens from rat (non-inflamed) plasma. One resistant and the second sensitive to rat glandular kallikreins.
    Enjyoji K; Kato H; Hayashi I; Oh-ishi S; Iwanaga S
    J Biol Chem; 1988 Jan; 263(2):965-72. PubMed ID: 3335530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor.
    Scott CF; Silver LD; Schapira M; Colman RW
    J Clin Invest; 1984 Apr; 73(4):954-62. PubMed ID: 6561202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen.
    Schapira M; Scott CF; Colman RW
    Biochemistry; 1981 May; 20(10):2738-43. PubMed ID: 6910423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic analysis of plasminogen activation by purified plasma kallikrein.
    Jörg M; Binder BR
    Thromb Res; 1985 Aug; 39(3):323-31. PubMed ID: 3850647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of factor XII in plasma from rats pretreated with tranexamic acid. Inhibition of a plasmin-induced loss of the functional activity of high molecular weight kininogen.
    Briseid K; Ryssdal AB
    Acta Pharmacol Toxicol (Copenh); 1980 Sep; 47(3):161-70. PubMed ID: 6449829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dextran-induced anaphylactoid reaction in man: altered reactivity of high molecular weight kininogen.
    Briseid G; Briseid K
    Acta Pharmacol Toxicol (Copenh); 1980 Aug; 47(2):119-26. PubMed ID: 6159774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of factor XII in rat plasma: protection by benzamidine of the cofactor function of high molecular weight kininogen.
    Briseid K; Berstad J
    Acta Pharmacol Toxicol (Copenh); 1981 Jul; 49(1):43-51. PubMed ID: 6175175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further characterization of monoclonal antibodies against rat plasma kallikrein, rat low molecular weight kininogen and synthetic bradykinin.
    Bedi GS; Back N
    Adv Exp Med Biol; 1989; 247B():223-30. PubMed ID: 2610064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic studies on surface-mediated activation of bovine factor XII and prekallikrein. Effects of kaolin and high-Mr kininogen on the activation reactions.
    Sugo T; Kato H; Iwanaga S; Takada K; Sakakibara S
    Eur J Biochem; 1985 Jan; 146(1):43-50. PubMed ID: 3871394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrolysis of rat high molecular weight kininogen by purified rat urinary kallikrein: identification of bradykinin as the kinin formed.
    Girolami JP; Alhenc-Gelas F; Dos Reis ML; Bascands JL; Suc JM; Corvol P; Menard J
    Adv Exp Med Biol; 1986; 198 Pt A():137-45. PubMed ID: 3643701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prekallikrein activator and kallikrein in acetone- and kaolin-activated rat plasma.
    Berstad J
    Acta Pharmacol Toxicol (Copenh); 1979 Sep; 45(3):174-80. PubMed ID: 506739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.